Page 2 - விசுவாசமான பள்ளத்தாக்கு மூலதனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Zhaoke Ophthalmology Limited (6622 HK) Announces Proposed Listing on the Main Board of SEHK_Final

Zhaoke Ophthalmology is an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs in China. Leveraging its deep domain expertise while designing the pipeline, the Company has initially placed strategic emphasis on five major ophthalmic indications in China in terms of market potential, including dry eye disease, or DED, wet age-related macular degeneration, or wAMD, diabetic macular edema, or DME, myopia and glaucoma. Up to now, the Company has built a comprehensive ophthalmic drug pipeline of 25 candidates that covers most major ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing.

United statesHong kongLi xiaoyiGoldman sachs asiaMatthews international capital managementGolden valley globalJefferies hong kongInternational placingZhaoke ophthalmologyOrbimed genesis master fundOrbimed partners master fundZhaoke investment fundHong kong zhaoke ophthalmology limitedCaas capital master fundCompany nanshaJennison associates

TodayIR: Zhaoke Ophthalmology Limited (6622 HK) Announces Proposed Listing on the Main Board of SEHK_Final

TodayIR: Zhaoke Ophthalmology Limited (6622.HK) Announces Proposed Listing on the Main Board of SEHK Final DJ EQS-News: Zhaoke Ophthalmology Limited (6622.HK) Announces Proposed Listing on the Main Board of SEHK Final EQS-News / 16/04/2021 / 11:26 UTC+8 Zhaoke Ophthalmology Limited (6622.HK) Launches Its HKPO with 8 Cornerstone Investors to Fuel Its Future Growth (April 16, 2021, Hong Kong) Zhaoke Ophthalmology Limited ( Zhaoke Ophthalmology or the Company ; stock code: 6622), an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs, announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ( SEHK ) today. Goldman Sachs (Asia) L.L.C., and Jefferies Hong Kong Limited are the Joint Sponsors, Joint Representatives, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers.

United statesHong kongLi xiaoyiKostenloser wertpapierhandelGoldman sachs asiaMatthews international capital managementGolden valley globalJefferies hong kongInternational placingZhaoke ophthalmologyZhaoke investment fundHong kong zhaoke ophthalmology limitedCompany nanshaJennison associatesMarketing pressOrbimed genesis master fund

Arctic Vision Announces Completion of Over US$100 Million Series B Financing to Accelerate Portfolio Expansion, Clinical Development and Commercialization

Arctic Vision Announces Completion of Over US$100 Million Series B Financing to Accelerate Portfolio Expansion, Clinical Development and Commercialization News provided by Share this article Share this article SHANGHAI, March 9, 2021 /PRNewswire/ Arctic Vision, a China-based clinical-stage ophthalmology company focused on developing innovative therapies for pan-ocular diseases, today announced the completion of over US$100 million Series B financing. The Series B round was led by Loyal Valley Capital, with participation from Tencent, Octagon Capital, and Dr. Adrian Cheng, renowned entrepreneur from New World Development Group, along with existing investors Nan Fung Life Sciences, Pivotal bioVenture Partners China and Morningside Ventures. The proceeds will continue to support the progress of Arctic Vision s pipeline, including clinical developments, registrational activities, and commercialization; as well as the establishment of in-house R&D capabilities; business development,

United statesAdrian chengRoy xieDianna qianChow tai fookInnocare pharmaJunshi biosciencesTeddy wuNan fung groupNan fung life sciencesWorld developmentChief executive officerBoard directorArctic visionLoyal valley capitalVenture partners china

Chinese ophthalmology firm Arctic Vision snags over $100m in Series B round

Chinese ophthalmology firm Arctic Vision snags over $100m in Series B round
dealstreetasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dealstreetasia.com Daily Mail and Mail on Sunday newspapers.

Hong kongRoy xieAdrian chengChow tai fookHong kong chanTeddy wuNan fung life sciencesWorld development groupArctic visionLoyal valleyOctagon capitalNew world development groupChow taiVenture partners chinaMorningside venturesLoyal valley capital

Arctic Vision Announces Completion of Over US$100 Million Series B Financing to Accelerate Portfolio Expansion, Clinical Development and Commercialization

Arctic Vision Announces Completion of Over US$100 Million Series B Financing to Accelerate Portfolio Expansion, Clinical Development and Commercialization
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesAdrian chengRoy xieDianna qianChow tai fookInnocare pharmaJunshi biosciencesTeddy wuNan fung groupNan fung life sciencesWorld developmentChief executive officerBoard directorArctic visionLoyal valley capitalVenture partners china